It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Although there is only symptomatic treatment for Fukuyama congenital muscular dystrophy (FCMD), several reports have suggested that steroid therapy could be effective for FCMD; however, no independent intervention studies have been conducted. This study aimed to evaluate the efficacy of steroid therapy for restoring motor functions in FCMD patients. This study involved 3-to-10-year-old FCMD patients who exhibited a decline in motor functions, requested steroid therapy. Patients with consent started oral administration of 0.5-mg/kg prednisolone every alternate day, which was increased to 1.0 mg/kg if the response was inadequate. We used the Gross Motor Function Measure (GMFM) to evaluate and compare the motor functions of all patients. Wilcoxon signed-rank test (significance level, P ≤ 0.05) was used for statistical analysis. At the onset of steroid therapy, 8.10 years (SD, 2.14 years) was the mean age of FCMD patients. The mean GMFM difference between before and after the steroid therapy was + 1.23 (SD, 1.10), and a P value of 0.015 represented significant improvement in GMFM. Our results indicate that steroid therapy may contribute to the maintenance and improvement of the motor functions of advanced-stage FCMD patients.
Clinical Trial Registration Registration Number: UMIN000020715, Registration Date: Feb 1st, 2016 (01/02/2016).
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Tokyo Women’s Medical University School of Medicine, Department of Pediatrics, Shinjuku, Japan (GRID:grid.410818.4) (ISNI:0000 0001 0720 6587); National Hospital Organization Higashisaitama National Hospital, Department of Clinical Research, Hasuda, Japan (GRID:grid.416698.4)
2 Tokyo Women’s Medical University School of Medicine, Department of Pediatrics, Shinjuku, Japan (GRID:grid.410818.4) (ISNI:0000 0001 0720 6587)
3 Tokyo Women’s Medical University, Department of Rehabilitation, Shinjuku, Japan (GRID:grid.410818.4) (ISNI:0000 0001 0720 6587)
4 National Center of Neurology and Psychiatry, Department of Clinical Epidemiology, Translational Medical Center, Kodaira, Japan (GRID:grid.419280.6) (ISNI:0000 0004 1763 8916)